SCHEMBL3920618

SCHEMBL3920618

C=CC1CCCN1S(=O)(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
ALDH1A1 P00352 3/20 0.47
TSHR P16473 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MMP2 P08253 2/20 0.46
MMP9 P14780 2/20 0.46
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45
NCSTN Q92542 1/20 0.45
APH1A Q96BI3 1/20 0.45
PSENEN Q9NZ42 1/20 0.45
FKBP1A P62942 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4310883 0.86 LMNA (0.52) LMNAALDH1A1TSHRL3MBTL1CYP3A4
SCHEMBL7188833 0.86 LMNA (0.52) LMNAALDH1A1TSHRL3MBTL1CYP3A4
SCHEMBL12005682 0.85 GAA (0.50) ALDH1A1TSHRL3MBTL1ACHEKDM4E
SCHEMBL14511106 0.79 ALDH1A1 (0.51) LMNAALDH1A1TSHRL3MBTL1RAB9A
SCHEMBL16439601 0.78 TSHR (0.43) LMNAALDH1A1TSHRL3MBTL1CYP3A4
SCHEMBL8207084 0.77 MMP1 (0.58) LMNAALDH1A1TSHRCYP2C19SMN1; SMN2
SCHEMBL13780083 0.76 PSEN1 (0.65) LMNATSHRL3MBTL1KMT2APSEN1
SCHEMBL12203854 0.76 PSEN1 (0.65) LMNATSHRL3MBTL1KMT2APSEN1
SCHEMBL6810343 0.76 PSEN1 (0.65) LMNATSHRL3MBTL1KMT2APSEN1
SCHEMBL16430372 0.75 TSHR (0.47) LMNAALDH1A1TSHRL3MBTL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC LMNA 4825/4885ALDH1A1 2621/4885TSHR 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.